North America and Europe Celiac Disease Market, By Treatment Type (Corticosteriods, Immunosuppressants and Others), Disease Type (Classical Celiac Disease, Non-Classical Celiac Disease, Refractory Celiac Disease, Potential Celiac Disease and Dermatitis Herpetiformis), Drug Type (Generics and Branded), Prescription Type (Prescription and Over The Counter), Dosage Form (Tablet, Capsules, Injection and Other), Route of Administration (Oral, Intravenous and Topical), Population Type (Children, Adults and Geriatric), End User (Hospitals, Clinics, Diagnostic Centres, Home Care Settings and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others) – Industry trends and forecast to 2031.
North America and Europe Celiac Disease Market Analysis and Insights
The market dynamics in North America and Europe for celiac disease are influenced by factors such as the rising prevalence of the condition, advancements in diagnostic technologies, and an expanding market for gluten-free products. Healthcare providers in these regions play a crucial role in creating awareness, conducting screenings, and implementing treatment strategies. Additionally, the growing interest in gluten-free diets as a lifestyle choice among the general population contributes to the expansion of the market.
Overall, the North America and Europe celiac disease market reflects a dynamic interplay of awareness, diagnosis, and research initiatives to improve the lives of individuals affected by this autoimmune condition. However, the market faces challenges such as the complexity of the disease and side effects associated with the drugs used for the treatment of celiac disease.
The North America celiac disease market is expected to gain market growth in the forecast period of 2024 to 2031. Data Bridge Market Research analyses that the market is growing with a CAGR of 9.8% in the forecast period of 2024 to 2031 and is expected to reach USD 193,364.33 Thousand by 2031 from USD 94,325.34 Thousand in 2023.
The Europe celiac disease market is expected to gain market growth in the forecast period of 2024 to 2031. Data Bridge Market Research analyses that the market is growing with a CAGR of 8.8% in the forecast period of 2024 to 2031 and is expected to reach USD 150,949.09 thousand by 2031 from USD 78,786.35 thousand in 2023.
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2020-2021)
|
|
Quantitative Units
|
Revenue in USD Thousand, Volumes in Units
|
|
Segments Covered
|
Treatment Type (Corticosteriods, Immunosuppressants and Others), Disease Type (Classical Celiac Disease, Non-Classical Celiac Disease, Refractory Celiac Disease, Potential Celiac Disease and Dermatitis Herpetiformis), Drug Type (Generics and Branded), Prescription Type (Prescription and Over The Counter), Dosage Form (Tablet, Capsules, Injection and Other), Route of Administration (Oral, Intravenous and Topical), Population Type (Children, Adults and Geriatric), End User (Hospitals, Clinics, Diagnostic Centres, Home Care Settings and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, Italy, Spain, U.K., Switzerland, Netherlands, Russia, Turkey, Poland, Sweden, Belgium, Denmark, Finland, Norway and Rest of Europe
|
|
Market Players Covered
|
Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals (subsidiary of Bausch Health Companies Inc.), Tillotts Pharma AG, GSK plc., ImmunogenX, Inc., Janssen Pharmaceuticals, Inc. (subsidiary of Johnson & Johnson Services, Inc.), Teva Pharmaceuticals USA, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Amgen Inc., AstraZeneca, Novartis AG, AdvaCare Pharma, ANOKION, Topas Therapeutics, Immunic Therapeutics and Equillium Bio. among others
|
Market Definition
Celiac disease, is a chronic autoimmune disorder characterized by an abnormal immune response to the ingestion of gluten—a protein found in wheat, barley, and rye. When individuals with celiac disease consume gluten, their immune system mistakenly attacks the lining of the small intestine, leading to inflammation and damage to the villi, finger-like projections responsible for nutrient absorption. This immune reaction results in a range of gastrointestinal and systemic symptoms, including abdominal pain, diarrhea, weight loss, fatigue, and nutritional deficiencies.
The diagnosis of celiac disease often involves a combination of blood tests to detect specific antibodies and confirmatory intestinal biopsy. The primary and lifelong treatment for celiac disease is a strict gluten-free diet. By eliminating gluten from their diet, individuals with celiac disease can manage symptoms, promote intestinal healing, and prevent complications. Adherence to a gluten-free lifestyle is crucial, as even small amounts of gluten can trigger immune responses and exacerbate the condition. Celiac disease can affect people of all ages, and while it is a lifelong condition, with proper management, individuals can lead healthy and fulfilling lives.
North America and Europe Celiac Disease Market Dynamics
Drivers
- Increasing Prevalence Of Celiac Disease
Celiac disease is an autoimmune disorder characterized by an intolerance to gluten, a protein found in wheat, barley, and rye. The prevalence of celiac disease has been on the rise in recent years, and several factors contribute to this increase.
In North America and Europe, where the westernized diet is prevalent, the shift towards increased gluten consumption further amplifies the market's growth. Thus increasing prevalence of celiac disease is expected to act as driver for the North America and Europe celiac disease market.
- Rising Demand For Gluten Containing Products
Gluten-containing products are made from ingredients that naturally contain gluten. This includes wheat-based products such as bread, pasta, pastries, and cereals. Barley and rye-based products also contain gluten.
In baking, gluten contributes to the rise and texture of bread and other baked goods. These ingredients are used in a variety of food items, from baked goods to pasta to certain sauces and processed foods.
The demand for gluten-containing products remains strong in North America and Europe due to consumer preferences, culinary traditions, and the cultural significance of certain foods. It reflects the broader consumer preference for traditional, gluten-rich foods in the region which will further increases the risk of celiac disease. Thus rising demand for gluten-containing products is expected to act as driver for the North America and Europe celiac disease market.
Restraint
- Complexity Of Celiac Disease
Celiac disease is a complex autoimmune disorder characterized by an abnormal immune response to gluten, a protein found in wheat, barley, rye, and their derivatives. The complexity of celiac disease arises from the intricate interplay of genetic, immunological, environmental, and dietary factors.
These complications make celiac disease a multifaceted and challenging autoimmune disorder to understand, diagnose, and manage. Thus complexity of celiac disease is expected to act as restraint for the North America and Europe celiac disease market.
Opportunity
- Emerging Biological Therapies For Celiac Disease
Emerging biological therapies for celiac disease represent a promising avenue for developing alternative treatments beyond the current standard of care, which is a lifelong strict gluten-free diet. While these therapies are still in the experimental stages and undergoing clinical trials, they hold the potential to address the complexity associated with celiac disease, offering new possibilities for individuals affected by this autoimmune disorder.
The development of biological therapies for celiac disease reflects a growing understanding of the underlying immunological mechanisms and a commitment to finding innovative solutions to improve the quality of life for individuals with this autoimmune disorder. As research progresses, these therapies may offer new options for the management of celiac disease beyond the limitations of a strict gluten-free diet. Thus emerging biological therapies for celiac disease is expected to act as opportunity for the North America and Europe celiac disease market.
Challenge
- Patient Adherence To Gluten-Free Diet
While patient adherence to a gluten-free diet is crucial for managing celiac disease, it presents challenges for the celiac disease market. The celiac disease market faces challenges because a strict gluten-free diet is currently the only effective treatment. With limited pharmaceutical interventions or alternative therapies available, the market heavily relies on patients adhering to dietary restrictions. This lack of treatment diversity limits revenue streams for pharmaceutical companies operating in the celiac disease space.
Patient adherence to a gluten-free diet poses challenges for the celiac disease market, particularly in terms of limited treatment options, economic considerations, and the impact on pharmaceutical development. Thus patient adherence to gluten-free diet is expected to act as challenge for the North America and Europe celiac disease market.
Recent Developments
- In October 2022, Takeda Pharmaceutical Company Limited, Zedira and Dr. Falk Pharma GmbH announced a collaboration and license agreement to develop ZED1227/TAK-227, a Phase 2b investigational drug in celiac disease. This collaboration will help the company to come up with the treatment of celiac disease
- In June 2020, Janssen Pharmaceuticals, Inc. announced collaboration with Monash University and signed a multi-year research to advance the understanding of the immune mechanisms underpinning Coeliac Disease and inform the development of new methods of diagnosis and treatment. The collaboration brings together leading researchers and industry partners to tackle this major health issue to develop innovative immunotherapeutics to prevent and treat celiac isease
North America and Europe Celiac Disease Market Scope
North America and Europe celiac disease market is categorized into nine notable segments based on treatment type, diagnosis, disease type, drug type, prescription type, dosage form, route of administration, population type, end user and distribution channel.The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Treatment Type
- Corticosteriods
- Immunosuppressants
- Others
On the basis of treatment type, the market is segmented into corticosteroids, immunosuppressants, and others.
Disease Type
- Refractory Celiac Disease
- Dermatitis Herpetiformis
- Potential Celiac Disease
- Classical Celiac Disease
- Non-Classical Celiac Disease
On the basis of disease type, the market is segmented into refractory celiac disease, dermatitis herpetiformis, potential celiac disease, classical celiac disease, and non-classical celiac disease.
Drug Type
- Generics
- Branded
On the basis of drug type, the market is segmented into branded and generics.
Prescription Type
- Prescription
- Over The Counter
On the basis of prescription type, the market is segmented into prescription and over the counter.
Dosage Form
- Tablet
- Capsules
- Injections
- Other
On the basis of dosage form, the market is segmented into tablet, capsules, injections, and others.
Route of Administration
- Oral
- Intravenous
- Topical
On the basis of route of administration, the market is segmented into oral, intravenous, and topical.
Population Type
- Adults
- Children
- Geriatric
On the basis of population type, the market is segmented into adults, children, and geriatric.
End-User
- Hospitals
- Clinics
- Home Care Settings
- Others
On the basis of end user, the market is segmented into hospitals, clinics, home care settings, and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others.
North America and Europe Celiac Disease Market Regional Analysis/Insights
The market is analyzed and market size insights and trends are provided by country, treatment type, diagnosis, disease type, drug type, prescription type, dosage form, route of administration, population type, end user and distribution channel as referenced above.
The countries covered in this market report U.S., Canada, Mexico, Germany, France, Italy, Spain, U.K., Switzerland, Netherlands, Russia, Turkey, Poland, Sweden, Belgium, Denmark, Finland, Norway and Rest of Europe.
The U.S. region is expected to dominate the market due to the strong presence of market players in the region. The Germany region is expected to dominate the market due to high prevalence of celiac disease and advanced healthcare infrastructure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and North America and Europe Celiac Disease Market Share Analysis
North America and Europe celiac disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, product type lifeline curve. The above data points provided are only related to the company’s focus on the North America and Europe celiac disease market.
Some of the major players operating in the North America and Europe celiac disease market are Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals (subsidiary of Bausch Health Companies Inc.), Tillotts Pharma AG, GSK plc., ImmunogenX, Inc., Janssen Pharmaceuticals, Inc. (subsidiary of Johnson & Johnson Services, Inc.), Teva Pharmaceuticals USA, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Amgen Inc., AstraZeneca, Novartis AG, AdvaCare Pharma, ANOKION, Topas Therapeutics, Immunic Therapeutics and Equillium Bio. among others.
SKU-